NCI-2023-09214Recruiting

Treatment with blinatumomab, a tyrosine kinase inhibitor, and chemotherapy for newly diagnosed B-cell acute lymphoblastic leukemia in children, adolescents, and young adults

Gender
Women and men
Age
1–46 years
Trial type
Interventional
Line of therapy
First line
Phase
Phase II

What is this trial about?

of the B-cell lineage (B-ALL) is a malignant disease of the hematopoietic system that occurs in children, adolescents, and young adults and is treated with chemotherapy administered in several treatment . The goal of this study is to investigate the efficacy and tolerability of the antibody in combination with a ( or ) and an adapted chemotherapy regimen. Women and men aged 1 year to under 46 years with newly diagnosed Ph+ B-ALL or Ph-like ABL-class B-ALL are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: B-cell Acute Lymphoblastic Leukemia (B-ALL)

Age: 1–46 years

Line of therapy: Erstlinie / bisher keine Therapie

Key inclusion criteria: newly diagnosed; Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like); Leukemic blasts must express CD19

Allocation

Stratifizierung anhand von Markern

Treatment

Follow-up

36 months

Detailed description

B-ALL originates in the bone marrow. There, immature precursor cells of —which are a type of white blood cell—undergo genetic changes. They stop maturing, multiply rapidly, and increasingly displace normal blood cell production. In -positive B-ALL, the BCR and ABL1 genes are fused together (BCR::ABL1), resulting in a persistently active protein from the tyrosine family that continuously signals the cells to proliferate and survive. In Ph-like B-ALL with an , genes such as ABL1, ABL2, CSF1R, or are rearranged instead, which can also result in a constantly active growth signal. Dasatinib and imatinib belong to the class of tyrosine kinase inhibitors; they are designed to inhibit such persistently active proteins and are taken as tablets. Blinatumomab is a that binds with one end to the protein on the surface of cells and with the other end to the body’s own immune cells, the , thereby bringing the two into close contact. It is administered as an infusion.

The aim of this Phase 2 study is to evaluate a treatment regimen in which three cycles of blinatumomab are incorporated into a modified standard chemotherapy regimen and consistently combined with a tyrosine kinase inhibitor, while omitting the usual consolidation chemotherapy. The main objectives () are at three years, as well as the safety and tolerability of this treatment. An additional objective is (OS) at three years. All patients will receive the study treatment; there is no control group. Assignment to the three parallel treatment groups is not random (non-) and is based on the genetic alteration of the leukemia cells: 1 for Ph+ B-ALL (dasatinib), Stratum 2 for an ABL-class gene fusion with PDGFRB (imatinib), and Stratum 3 for such a fusion without PDGFRB (dasatinib). The study is open-label, meaning that both the patients and the study physicians know which treatment is being administered. Treatment lasts for approximately two years from the start of . In addition, medications are administered into the cerebrospinal fluid—the fluid surrounding the brain and spinal cord—to prevent or treat involvement of the nervous system. During the course of the study, blood, cerebrospinal fluid, and bone marrow samples will be collected, and heart function will be monitored.

Patients between the ages of one and under 46 whose leukemia cells express CD19 are eligible to participate. Induction therapy must have already begun or been completed, and a tyrosine kinase inhibitor may have been administered only for a short time prior to enrollment. Patients who are ineligible include, among others, those with a history of or leukemia resulting from prior cancer treatment.

Facts

  1. Disease: of the B-cell lineage (B-ALL)
  2. Cancer characteristics: newly diagnosed, -positive (BCR::ABL1) or Philadelphia chromosome-like with an (ABL1, ABL2, CSF1R, or ), -positive cells
  3. What the study investigates: Efficacy and tolerability of in combination with a ( or ) and tailored chemotherapy without the usual consolidation chemotherapy
  4. Study objective: To estimate at three years and to describe the safety and tolerability of this treatment
  5. Study duration: Treatment for approximately two years from the start of ; evaluation of the at three years
  6. Study characteristics: Phase 2 study, non-, three parallel treatment groups, assignment based on genetic cancer characteristics, open-label

Trial sites

1 trial site in Germany is listed.

  • UKSH - Universitätsklinikum Schleswig-Holstein

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.